Dapagliflozin associated with lower AF risk: study
The finding adds to evidence of the diabetes drug's cardiac benefit
Patients with type 2 diabetes who are prescribed the SGLT-2 inhibitor dapagliflozin have a lower risk of developing both atrial fibrillation (AF) and atrial flutter than those on placebo, a US study suggests.
The findings from the DECLARE-TIMI (Dapagliflozin Effect on Cardiovascular Events – Thrombolysis in Myocardial Infarction) 58 trial also show that these cardio-protective effects persist regardless of prior CVD history, the researchers say.
